In 2025, Royalty Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Royalty Pharma has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 0a | 0a | 0a | |
Total Scope 2 | ||||
Market-Based | 268a | 0a | 0a | |
Location-Based | 268a | 0a | 0a | |
Total Scope 3 | 20,927a | 23,266a | 32,002a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0a | 0a | 0a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Royalty Pharma amounted to 268 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Royalty Pharma increased by ∞%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Royalty Pharma were 0 metric tons of CO₂ equivalent (tCO₂e).a
In 2025, Royalty Pharma reported Scope 2 greenhouse gas (GHG) emissions of 268 tCO₂e using the market-based method and 268 tCO₂e using the location-based method.a
In 2025, Royalty Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Royalty Pharma reported 20,927 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Royalty Pharma includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Royalty Pharma reported total Scope 3 emissions of 20,927 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 0% of these emissions originated from upstream activities such as purchased goods and capital goods, while 100% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2021, Royalty Pharma's Scope 3 emissions have increased by 13.46%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2024), Royalty Pharma's Scope 3 emissions decreased by 10.05%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2025, Royalty Pharma reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2025, the largest contributors to Royalty Pharma's Scope 3 emissions were:a
In 2025, Royalty Pharma reported a total carbon footprint of 21,195 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 8.9% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Royalty Pharma's total carbon footprint was Scope 3 emissions, accounting for 98.74% of the company's total carbon footprint, followed by Scope 2 emissions at 1.26%.a